A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

← catalyst calendar

NCT04998747

Sponsored by Amgen (industry) · AMGN — their whole pipeline →.

Phase

Phase 1

Status

Withdrawn

Study type

Interventional

Design

Non randomized · None · Basic science

Enrollment

0actual

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Amgen Decision to stop development of AMG 701 SC, not for safety reasons but for business reasons.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-08-29

estimated

When the study began enrolling

Primary completion

2025-08-02

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-08-28

estimated

The whole study's end, after follow-up

First posted

2021-08-10

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2022-09-27

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Relapsed/Refractory Multiple Myeloma

Interventions

Drug: AMG 701
Drug: AMG 701

Primary outcomes

what the primary-completion date above is the date OF

Number of participants who experience dose-limiting toxicities (DLTs)

measured 28 days

Number of participants who experience one or more treatment-emergent adverse events (TEAEs)